These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 22040533

  • 1. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
    Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE.
    Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533
    [Abstract] [Full Text] [Related]

  • 2. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD, Korean Academy of Tuberculosis and Respiratory Diseases study group, Korea Chronic Obstructive Pulmonary Disease study group.
    Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
    [Abstract] [Full Text] [Related]

  • 3. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ.
    Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
    [Abstract] [Full Text] [Related]

  • 4. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
    Cazzola M, Andò F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, D'Amato M.
    Pulm Pharmacol Ther; 2007 Jul; 20(5):556-61. PubMed ID: 16914336
    [Abstract] [Full Text] [Related]

  • 5. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y.
    Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
    [Abstract] [Full Text] [Related]

  • 6. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 7. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED, van Dyk M, Sagriotis A.
    Pulm Pharmacol Ther; 2008 Aug; 21(1):20-5. PubMed ID: 17118684
    [Abstract] [Full Text] [Related]

  • 8. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
    Tashkin DP, Hanania NA, McGinty J, Denis-Mize K, Chaudry I.
    Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
    [Abstract] [Full Text] [Related]

  • 9. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
    Dalal AA, Candrilli SD, Davis KL.
    Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
    [Abstract] [Full Text] [Related]

  • 10. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
    Fang LZ, Liang X, Zhang JQ, Liu L, Fu WP, Zhao ZH, Dai LM.
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
    [Abstract] [Full Text] [Related]

  • 11. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M, Ohtawa J.
    Respirology; 2011 Jan; 16(1):95-101. PubMed ID: 20920142
    [Abstract] [Full Text] [Related]

  • 12. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis.
    Liu Y, Shi H, Sun X, Zhang D, Zhang Y, Yang K, Mi L, Li M.
    Eur J Intern Med; 2014 Jun; 25(5):491-5. PubMed ID: 24816076
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators.
    N Engl J Med; 2007 Feb 22; 356(8):775-89. PubMed ID: 17314337
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.
    Frith PA, Thompson PJ, Ratnavadivel R, Chang CL, Bremner P, Day P, Frenzel C, Kurstjens N, Glisten Study Group.
    Thorax; 2015 Jun 22; 70(6):519-27. PubMed ID: 25841237
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
    Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T.
    Am J Respir Crit Care Med; 2002 Oct 15; 166(8):1084-91. PubMed ID: 12379552
    [Abstract] [Full Text] [Related]

  • 18. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
    O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K.
    Chest; 2006 Sep 15; 130(3):647-56. PubMed ID: 16963658
    [Abstract] [Full Text] [Related]

  • 19. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
    Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM, POET-COPD Investigators.
    N Engl J Med; 2011 Mar 24; 364(12):1093-1103. PubMed ID: 21428765
    [Abstract] [Full Text] [Related]

  • 20. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R, Make B.
    COPD; 2008 Aug 24; 5(4):221-7. PubMed ID: 18671147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.